Merck to split business into oncology and non-oncology units Split does not involve its animal health division Key patents on Keytruda will begin to expire in 2028 Feb 23 (Reuters) - Merck (MRK.N), ...

(Bloomberg) -- Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its ...

Feb 23 (Reuters) - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of patent for its top-selling drug Keytruda, the Wall Street Journal ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

(Reuters) Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent expiry of ...

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo Feb 23 (Reuters) - Merck is splitting its ...